BCYC RSI Chart
Last 7 days
4.8%
Last 30 days
1.1%
Last 90 days
37.7%
Trailing 12 Months
21.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 15.5M | 22.5M | 24.8M | 27.0M |
2022 | 13.7M | 16.3M | 15.0M | 14.5M |
2021 | 11.1M | 11.3M | 11.8M | 11.7M |
2020 | 8.5M | 8.6M | 11.8M | 10.4M |
2019 | 10.7M | 10.6M | 9.6M | 13.8M |
2018 | 3.3M | 4.6M | 5.9M | 7.1M |
2017 | 0 | 0 | 0 | 2.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 20, 2024 | sands stephen h. | acquired | - | - | 12,000 | - |
Feb 06, 2024 | arroyo santiago | acquired | - | - | 21,660 | chief development officer |
Jan 03, 2024 | crockett nigel | sold | -46,252 | 17.5 | -2,643 | chief business officer |
Jan 03, 2024 | lee kevin | sold | -152,302 | 17.5 | -8,703 | chief executive officer |
Jan 03, 2024 | milnes alistair | sold | -46,252 | 17.5 | -2,643 | chief operating officer |
Jan 03, 2024 | thompson travis alvin | sold | -10,570 | 17.5 | -604 | chief accounting officer |
Jan 03, 2024 | skynner michael | sold | -46,252 | 17.5 | -2,643 | chief technology officer |
Jan 03, 2024 | keen nicholas | sold | -46,200 | 17.5 | -2,640 | chief scientific officer |
Jan 02, 2024 | thompson travis alvin | acquired | - | - | 16,000 | chief accounting officer |
Jan 02, 2024 | legault pierre | acquired | - | - | 12,000 | - |
Which funds bought or sold BCYC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 27, 2024 | NOMURA HOLDINGS INC | unchanged | - | -804,000 | 7,232,000 | 0.02% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 136,684 | 136,684 | -% |
Feb 21, 2024 | Raleigh Capital Management Inc. | sold off | -100 | -3,717 | - | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -53.32 | -6,909,000 | 5,006,000 | -% |
Feb 15, 2024 | Legal & General Group Plc | added | 43.63 | 539,431 | 2,399,790 | -% |
Feb 15, 2024 | WEXFORD CAPITAL LP | new | - | 630,612 | 630,612 | 0.14% |
Feb 15, 2024 | Virtus ETF Advisers LLC | added | 66.59 | 37,157 | 111,590 | 0.07% |
Feb 15, 2024 | HORIZON KINETICS ASSET MANAGEMENT LLC | reduced | -4.03 | -41,070 | 260,280 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 8,847 | 268,000 | 272,000 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | added | 68.00 | 507,812 | 1,499,740 | -% |
Unveiling Bicycle Therapeutics Ltd's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bicycle Therapeutics Ltd)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 40.7B | 6.8B | -8.64 | 5.95 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.8B | 1.8B | -42.76 | 10.3 | ||||
BMRN | 16.5B | 2.4B | 98.3 | 6.81 | ||||
INCY | 12.8B | 3.7B | 21.4 | 3.46 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.41 | 17.87 | ||||
BBIO | 5.4B | - | -8.32 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.8 | 13.97 | ||||
ARWR | 3.5B | 240.7M | -11.94 | 14.72 | ||||
ACAD | 3.0B | 726.4M | -49.71 | 4.19 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.31 | 4.72 | ||||
NVAX | 669.0M | 983.7M | -1.23 | 0.68 | ||||
CRBP | 411.7M | 881.7K | -9.23 | 466.16 | ||||
INO | 324.4M | 4.9M | -2.4 | 66.66 | ||||
IBIO | 14.1M | 2.1M | -0.52 | 2.14 |
Bicycle Therapeutics Ltd News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -0.4% | 5,331,000 | 5,352,000 | 11,397,000 | 4,896,000 | 3,185,000 | 3,040,000 | 4,378,000 | 3,860,000 | 3,771,000 | 4,333,000 | 1,785,000 | 1,808,000 | 3,848,000 | 3,842,000 | 1,571,000 | 1,129,000 | 5,281,000 | 614,000 | 1,522,000 | 6,384,000 | 1,057,000 |
Operating Expenses | 6.1% | 59,566,000 | 56,149,000 | 54,508,000 | 46,699,000 | 35,396,000 | 32,799,000 | 31,678,000 | 31,243,000 | 21,794,500 | 18,627,000 | 19,062,000 | 17,832,000 | 20,907,000 | 14,517,000 | 14,154,000 | 12,772,000 | 10,045,000 | 10,867,000 | 9,510,000 | 9,678,000 | 8,599,000 |
S&GA Expenses | -8.7% | 14,869,000 | 16,281,000 | 14,788,000 | 14,488,000 | 10,677,000 | 10,047,000 | 11,824,000 | 16,959,000 | 8,840,500 | 8,114,000 | 7,340,000 | 8,139,000 | 10,851,500 | 7,154,000 | 6,196,000 | 4,998,000 | 3,396,000 | 4,789,000 | 2,973,000 | 3,402,000 | 2,106,000 |
R&D Expenses | 12.1% | 44,697,000 | 39,868,000 | 39,720,000 | 32,211,000 | 24,719,000 | 22,752,000 | 19,854,000 | 14,284,000 | 12,954,000 | 10,513,000 | 11,722,000 | 9,693,000 | 10,056,000 | 7,363,000 | 7,958,000 | 7,774,000 | 6,649,000 | 6,078,000 | 6,537,000 | 6,276,000 | 6,493,000 |
EBITDA Margin | -3.1% | -6.28 | -6.09 | -5.89 | -7.60 | -7.41 | -6.42 | -5.14 | -5.47 | -5.48 | -5.55 | -5.40 | -4.98 | -4.81 | - | - | - | - | - | - | - | - |
Interest Expenses | 0.7% | 820,000 | 814,000 | 821,000 | 808,000 | 826,000 | 817,000 | 883,000 | 818,000 | 820,000 | 823,000 | 819,000 | 522,000 | - | - | - | - | - | - | - | - | - |
Income Taxes | -86.3% | 315,500 | 2,300,000 | -517,000 | -600,000 | -429,500 | -238,000 | -447,000 | -400,000 | -755,500 | -400,000 | -200,000 | -300,000 | -55,000 | -465,000 | -97,000 | -100,000 | -138,000 | -331,000 | 135,000 | 80,000 | - |
Earnings Before Taxes | -2.4% | -48,779,000 | -47,626,000 | -43,120,000 | -39,682,000 | -30,398,000 | -28,585,000 | -27,275,000 | -27,983,000 | -18,785,000 | -15,093,000 | -18,073,000 | -16,531,000 | -17,488,000 | -10,603,000 | -12,212,000 | -11,431,000 | -4,544,000 | -9,813,000 | -10,082,000 | -6,423,000 | -6,641,000 |
EBT Margin | -2.6% | -6.64 | -6.48 | -6.30 | -8.13 | -7.90 | -6.82 | -5.45 | -5.81 | -5.85 | -5.71 | -5.56 | -5.13 | -4.98 | - | - | - | - | - | - | - | - |
Net Income | 1.6% | -49,099,000 | -49,898,000 | -42,603,000 | -39,064,000 | -29,978,000 | -28,347,000 | -26,828,000 | -27,564,000 | -18,037,000 | -14,678,000 | -17,913,000 | -16,191,000 | -17,433,000 | -10,138,000 | -12,115,000 | -11,324,000 | -4,406,000 | -9,482,000 | -10,217,000 | -6,503,000 | -6,641,000 |
Net Income Margin | -2.9% | -6.70 | -6.51 | -6.22 | -8.01 | -7.79 | -6.70 | -5.33 | -5.69 | -5.71 | -5.62 | -5.47 | -5.05 | -4.91 | - | - | - | - | - | - | - | - |
Free Cashflow | -3000.1% | -47,339,000 | -1,527,000 | 33,819,000 | -48,510,000 | -31,757,000 | -8,855,000 | -33,330,000 | -31,156,000 | -11,502,000 | 21,549,000 | -12,541,000 | -14,330,000 | -17,101,000 | - | - | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
Assets | -6.8% | 595 | 639 | 454 | 429 | 411 | 417 | 445 | 460 | 480 | 281 | 226 | 224 | 161 | 170 | 119 | 129 | 110 | 116 | 126 | 82.00 |
Current Assets | -6.8% | 562 | 603 | 408 | 381 | 369 | 381 | 408 | 430 | 459 | 273 | 218 | 215 | 156 | 164 | 113 | 123 | 104 | 110 | 120 | 77.00 |
Cash Equivalents | -8.0% | 526 | 572 | 340 | 294 | 339 | 361 | 373 | 407 | 439 | 260 | 199 | 196 | 136 | 150 | 97.00 | 110 | 92.00 | 96.00 | 109 | 63.00 |
Net PPE | -6.9% | 15.00 | 16.00 | 18.00 | 18.00 | 19.00 | 16.00 | 17.00 | 9.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | 0.8% | 224 | 223 | 234 | 186 | 140 | 128 | 134 | 129 | 134 | 111 | 84.00 | 82.00 | 66.00 | 61.00 | 48.00 | 47.00 | 17.00 | 21.00 | 22.00 | 29.00 |
Current Liabilities | -0.3% | 70.00 | 70.00 | 72.00 | 53.00 | 53.00 | 42.00 | 41.00 | 35.00 | 36.00 | 30.00 | 23.00 | 21.00 | 23.00 | 17.00 | 17.00 | 16.00 | 9.00 | 9.00 | 9.00 | 9.00 |
Long Term Debt | 0.3% | 31.00 | 31.00 | 31.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 29.00 | 15.00 | 14.00 | - | - | - | - | - | - |
LT Debt, Non Current | 0.3% | 31.00 | 31.00 | 31.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 29.00 | 15.00 | 14.00 | - | - | - | - | - | - |
Shareholder's Equity | -10.8% | 371 | 416 | 220 | 243 | 271 | 289 | 311 | 330 | 346 | 171 | 142 | 142 | 95.00 | 110 | 71.00 | 82.00 | 93.00 | 95.00 | 105 | - |
Retained Earnings | -10.6% | -511 | -462 | -412 | -370 | -331 | -301 | -272 | -245 | -218 | -200 | -185 | -167 | -151 | -134 | -123 | -111 | -100 | -96.14 | -86.66 | -69.94 |
Additional Paid-In Capital | 0.9% | 883 | 875 | 633 | 613 | 601 | 590 | 584 | 578 | 568 | 374 | 331 | 313 | 250 | 246 | 199 | 197 | 195 | 194 | 193 | 2.00 |
Shares Outstanding | 0.1% | 42.00 | 42.00 | 31.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 25.00 | 24.00 | 24.00 | 22.00 | 19.00 | - | - | - | - | - | - | - |
Float | - | - | - | 767 | - | - | - | 490 | - | - | - | 718 | - | - | - | 190 | - | - | - | 114 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -4513.5% | -47,288 | -1,025 | 34,096 | -46,411 | -30,309 | -5,871 | -23,531 | -26,400 | -10,435 | 21,718 | -12,370 | -13,707 | -16,617 | -9,985 | -12,349 | 21,162 | -4,919 | -10,885 | -7,608 | -5,201 | -8,854 |
Share Based Compensation | 5.1% | 7,812 | 7,430 | 8,193 | 9,042 | 5,540 | 5,368 | 5,673 | 10,198 | 2,999 | 2,688 | 2,575 | 3,821 | 1,564 | 1,510 | 1,319 | 2,121 | 1,083 | 819 | 905 | 276 | 207 |
Cashflow From Investing | 89.8% | -51.00 | -502 | -277 | -2,099 | -1,448 | -2,984 | -9,799 | -4,756 | -1,067 | -169 | -171 | -623 | -484 | -95.00 | -301 | -320 | -391 | -283 | -463 | -418 | -410 |
Cashflow From Financing | -99.8% | 386 | 234,631 | 12,292 | 2,718 | 5,888 | 159 | 195 | 450 | 190,664 | 40,450 | 15,552 | 74,059 | 1,744 | 61,087 | 10.00 | 2.00 | 122 | -811 | 59,095 | 34.00 | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Consolidated Statements of Operations and Comprehensive Loss | |||
Collaboration revenues | $ 26,976 | $ 14,463 | $ 11,697 |
Operating expenses: | |||
Research and development | 156,496 | 81,609 | 44,880 |
General and administrative | 60,426 | 49,507 | 32,435 |
Total operating expenses | 216,922 | 131,116 | 77,315 |
Loss from operations | (189,946) | (116,653) | (65,618) |
Other income (expense): | |||
Interest income | 14,002 | 5,756 | 120 |
Interest expense | (3,263) | (3,344) | (2,984) |
Total other income (expense), net | 10,739 | 2,412 | (2,864) |
Net loss before income tax provision | (179,207) | (114,241) | (68,482) |
Provision for (benefit from) income taxes | 1,457 | (1,524) | (1,663) |
Net loss | $ (180,664) | $ (112,717) | $ (66,819) |
Net loss per share, basic | $ (5.08) | $ (3.80) | $ (2.67) |
Net loss per share, diluted | $ (5.08) | $ (3.80) | $ (2.67) |
Weighted average ordinary shares outstanding, basic | 35,592,362 | 29,660,659 | 25,061,734 |
Weighted average ordinary shares outstanding, diluted | 35,592,362 | 29,660,659 | 25,061,734 |
Comprehensives loss: | |||
Net Income (Loss) | $ (180,664) | $ (112,717) | $ (66,819) |
Other comprehensive (loss) income: | |||
Foreign currency translation adjustment | (1,691) | 3,775 | (195) |
Total comprehensive loss | $ (182,355) | $ (108,942) | $ (67,014) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 526,423 | $ 339,154 |
Accounts receivable | 0 | 2,045 |
Prepaid expenses and other current assets | 11,406 | 9,022 |
Research and development incentives receivable | 24,039 | 19,162 |
Total current assets | 561,868 | 369,383 |
Property and equipment, net | 14,515 | 19,110 |
Operating lease right-of-use assets | 13,169 | 13,658 |
Other assets | 5,792 | 8,458 |
Total assets | 595,344 | 410,609 |
Current liabilities: | ||
Accounts payable | 13,050 | 6,472 |
Accrued expenses and other current liabilities | 31,509 | 26,452 |
Deferred revenue, current portion | 24,978 | 20,418 |
Total current liabilities | 69,537 | 53,342 |
Long-term debt, net of discount | 30,698 | 30,315 |
Operating lease liabilities, net of current portion | 9,382 | 10,885 |
Deferred revenue, net of current portion | 110,216 | 41,455 |
Other longterm liabilities | 4,579 | 3,829 |
Total liabilities | 224,412 | 139,826 |
Commitments and contingencies (Note 11) | ||
Shareholders' equity: | ||
Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 59,612,613 and 57,820,181 shares authorized at December 31, 2023 and December 31, 2022, respectively; 42,431,766 and 29,873,893 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 550 | 387 |
Additional paid-in capital | 883,446 | 601,105 |
Accumulated other comprehensive (loss) income | (1,304) | 387 |
Accumulated deficit | (511,760) | (331,096) |
Total shareholders' equity | 370,932 | 270,783 |
Total liabilities and shareholders' equity | $ 595,344 | $ 410,609 |
 | www.bicycletherapeutics.com |
---|---|
 | 236 |